MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Cancer Cell

• Publication date

  2017-07-10

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.ccell.2017.06.004PMID 28697344PMCID PMC5533091
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer

  2017cited by this paper
• Validation of Metabolic Alterations in Microscale Cell Culture Lysates Using Hydrophilic Interaction Liquid Chromatography (HILIC)-Tandem Mass Spectrometry-Based Metabolomics

  2016influential reference
• Using MetaboAnalyst 3.0 for Comprehensive Metabolomics Data Analysis

  2016influential reference
• Inhibition of Lipid Oxidation Increases Glucose Metabolism and Enhances 2-Deoxy-2-[18F]Fluoro-d-Glucose Uptake in Prostate Cancer Mouse Xenografts

  2015cited by this paper
• Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer.

  2014cited by this paper
• MVAPACK: A Complete Data Handling Package for NMR Metabolomics

  2014influential reference
• Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia

  2014cited by this paper
• MUC1: a novel metabolic master regulator.

  2014cited by this paper
• Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase

  2014cited by this paper
• A pilot phase II Study of digoxin in patients with recurrent prostate cancer as evident by a rising PSA.

  2013influential reference
• HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations.

  2013cited by this paper
• Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

  2013cited by this paper
• Differential Expression of Metabolic Genes in Tumor and Stromal Components of Primary and Metastatic Loci in Pancreatic Adenocarcinoma

  2012influential reference
• MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancer

  2012influential reference
• Faculty Opinions recommendation of Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism.

  2012cited by this paper
• A positive/negative ion–switching, targeted mass spectrometry–based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue

  2012cited by this paper
• Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism.

  2012cited by this paper
• HMDB 3.0—The Human Metabolome Database in 2013

  2012cited by this paper
• Suppression of dual-specificity phosphatase-2 by hypoxia increases chemoresistance and malignancy in human cancer cells.

  2011cited by this paper
• Pyruvate carboxylase is required for glutamine-independent growth of tumor cells

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

  2011cited by this paper
• Preclinical Activity of the Rational Combination of Selumetinib (AZD6244) in Combination with Vorinostat in KRAS-Mutant Colorectal Cancer Models

  2011cited by this paper
• HIF-1-dependent Expression of Angiopoietin-like 4 and L1CAM Mediates Vascular Metastasis of Hypoxic Breast Cancer Cells to the Lungs

  2011cited by this paper
• The reactive tumor microenvironment: MUC1 signaling directly reprograms transcription of CTGF

  2010cited by this paper
• Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics

  2010cited by this paper
• Rethinking the Warburg effect with Myc micromanaging glutamine metabolism.

  2010cited by this paper
• Imatinib-resistance associated with BCR-ABL upregulation is dependent on HIF-1α-induced metabolic reprogramming

  2010cited by this paper
• HIF-1alpha and calcium signaling as targets for treatment of prostate cancer by cardiac glycosides.

  2009cited by this paper
• Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation

  2009cited by this paper
• Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice

  2009cited by this paper
• Regulation of oxygen homeostasis by hypoxia-inducible factor 1.

  2009cited by this paper
• NMR-based characterization of metabolic alterations in hypertension using an adaptive, intelligent binning algorithm.

  2008cited by this paper
• Phosphorylation of MUC1 by Met Modulates Interaction with p53 and MMP1 Expression*

  2008cited by this paper
• Analyzing real-time PCR data by the comparative CT method

  2008cited by this paper
• The biology of cancer: metabolic reprogramming fuels cell growth and proliferation.

  2008cited by this paper
• Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth

  2008cited by this paper
• Metabolite identification via the Madison Metabolomics Consortium Database

  2008cited by this paper
• PRIMe: A Web Site That Assembles Tools for Metabolomics and Transcriptomics

  2008cited by this paper
• Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells.

  2007cited by this paper
• SOGGY: solvent-optimized double gradient spectroscopy for water suppression. A comparison with some existing techniques.

  2007cited by this paper
• Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.

  2006cited by this paper
• Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1α gene

  2006cited by this paper
• Hypoxia Increases Resistance of Human Pancreatic Cancer Cells to Apoptosis Induced by Gemcitabine

  2004cited by this paper
• Targeting HIF-1 for cancer therapy

  2003cited by this paper
• Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer.

  2000cited by this paper
• Pancreatic tumors show high levels of hypoxia.

  2000cited by this paper
• Energy metabolism of human LoVo colon carcinoma cells: correlation to drug resistance and influence of lonidamine.

  2000cited by this paper
• Leflunomide Inhibits Pyrimidine de Novo Synthesis in Mitogen-stimulated T-lymphocytes from Healthy Humans*

  1998influential reference
• Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil.

  1997cited by this paper

• Evolution of the MUC1 gene in eutherian mammals as an adaptation responsible for the increasing incidence of cancer in humans.

  2026cites this paper
• Integrative Transcriptomic and Proteomic Profiling Defines Secretory and Immune Related Subtypes in Pancreatic Ductal Adenocarcinoma.

  2026cites this paper
• Involvement of Non-Coding RNAs in the Glucose Metabolic Reprogramming of Oral Squamous Cell Carcinoma: From Mechanisms to Therapeutics

  2026cites this paper
• Navigating the complexities of ferroptosis in pancreatic ductal adenocarcinoma: roles, mechanisms and potential applications.

  2026cites this paper
• Therapeutic cancer vaccines in pancreatic cancer

  2025cites this paper
• CDK7 as a New therapeutic target in pancreatic and lung cancer: current evidence and future perspectives

  2025cites this paper
• The role of synthetic lethality in overcoming cancer therapy resistance: Emerging paradigm and recent advances.

  2025cites this paper
• De novo pyrimidine biosynthesis inhibition synergizes with BCL-XL targeting in pancreatic cancer

  2025cites this paper
• Tumor-stromal metabolic crosstalk in pancreatic cancer.

  2025cites this paper
• Decipher the single-cell level responses to chemotherapy in pancreatic ductal adenocarcinoma by a cross-time context graph model.

  2025cites this paper
• Leveraging Cancer Metabolism to Translate into Effective Therapeutics.

  2025cites this paper
• Mitochondria-Centric Lipid Metabolism and Inter-Organelle Crosstalk in Pancreatic Cancer: Unveiling Novel Therapies.

  2025cites this paper
• Mitochondrial Ca2+ uniporter haploinsufficiency leads to sexually dimorphic redox imbalance and metabolic remodelling in the mouse brain.

  2025cites this paper
• Molecular, metabolic, and histological subtypes of pancreatic ductal adenocarcinoma and its tumor microenvironment: Insights into tumor heterogeneity and clinical implications.

  2025cites this paper
• Niclosamide-Loaded Polyanhydride Nanoparticles to Combat Gemcitabine Resistance in Pancreatic Cancer

  2025cites this paper
• The Pentose Phosphate Pathway: From Mechanisms to Implications for Gastrointestinal Cancers

  2025cites this paper
• CLT-003 exerts anti-tumor activity in pancreatic cancer by blocking the PI3K/AKT/HIF-1α pathway

  2025cites this paper
• A stumbling block in pancreatic cancer treatment: drug resistance signaling networks

  2025cites this paper
• Histone H1 deamidation facilitates chromatin relaxation for DNA repair

  2025cites this paper
• The perspective of targeting cancer cell metabolism: combination therapy approaches

  2025cites this paper
• Genistein as a Chemo-modulatory Agent: Exploring its Potential in Chemosensitization and Combinatorial Therapeutic Strategies for Cancer Treatment.

  2025cites this paper
• FOSL1 transcriptionally dictates the Warburg effect and enhances chemoresistance in triple-negative breast cancer

  2025cites this paper
• Analysis of an engineered organoid model of pancreatic cancer identifies hypoxia as a contributing factor in determining transcriptional subtypes

  2025cites this paper
• Unraveling the glyco-immunity nexus in pancreatic cancer

  2025cites this paper
• Responsive nanomedicine strategies achieve pancreatic cancer precise theranostics

  2025cites this paper
• Uridine as a hub in cancer metabolism and RNA biology

  2025cites this paper
• Role and molecular mechanisms of hypoxia-derived exosomal miR-301a on gemcitabine resistance in pancreatic cancer

  2025cites this paper
• HypoxamiRs in pancreatic cancer: master regulators of the hypoxic tumor microenvironment

  2025cites this paper
• Downregulation of MUC1 Enhances Antitumor Response in Colon Cancer Model by Decreasing PD‐L1 Expression In Vivo and In Vitro

  2025cites this paper
• The deubiquitylase OTUB1 drives gemcitabine resistance in pancreatic cancer by enhancing pyrimidine metabolism through modulating DHODH mRNA stability

  2025cites this paper
• Navigating the Paradox of Senescence and Chemoresistance in Pancreatic Cancer.

  2025cites this paper
• Niclosamide nanoparticles enhance pancreatic cancer sensitivity to gemcitabine via HIF-1α inhibition

  2025cites this paper
• Glutaminase-2 Expression Induces Metabolic Changes and Regulates Pyruvate Dehydrogenase Activity in Glioblastoma Cells

  2025cites this paper
• Silibinin Anticancer Effects Through the Modulation of the Tumor Immune Microenvironment in Triple-Negative Breast Cancer

  2025cites this paper
• Inhibition of autophagy by Atg7 knockdown enhances chemosensitivity in gemcitabine/paclitaxel-resistant pancreatic cancer MIAPaCa2 cells.

  2025cites this paper
• The role of transketolase in the immunotherapy and prognosis of hepatocellular carcinoma: a multi-omics approach

  2025cites this paper
• KRASG12D-driven pentose phosphate pathway remodeling imparts a targetable vulnerability synergizing with MRTX1133 for durable remissions in PDAC

  2025cites this paper
• Exploring the potential of gemcitabine-metal–organic frameworks in combating pancreatic cancer under ketogenic conditions

  2025cites this paper
• The Oncoprotein Mucin 1 in Pancreatic Cancer Onset and Progression: Potential Clinical Implications

  2025cites this paper
• CDCA7 enhances STAT3 transcriptional activity to regulate aerobic glycolysis and promote pancreatic cancer progression and gemcitabine resistance

  2025cites this paper
• Targeted mitochondrial therapy for pancreatic cancer

  2025cites this paper
• Integration of Metabolomics and Transcriptomics Uncovers the Adjuvant Effects of Matrine Combined With Gemcitabine on Pancreatic Cancer Treatment

  2025cites this paper
• Lactylation of XLF promotes non-homologous end-joining repair and chemoresistance in cancer.

  2025cites this paper
• Metabolic reprogramming of drug resistance in pancreatic cancer: mechanisms and effects.

  2025cites this paper
• What’s on the menu?: metabolic constraints in the pancreatic tumor microenvironment

  2025cites this paper
• Mucin-1: a promising pan-cancer therapeutic target

  2025cites this paper
• Mechanistic and functional characterization of ABTB2 as a novel target for pancreatic cancer therapy

  2025cites this paper
• Systematic and comprehensive insights into HIF-1 stabilization under normoxic conditions: implications for cellular adaptation and therapeutic strategies in cancer

  2025cites this paper
• INHBA promotes chemoresistance in pancreatic cancer by enhancing CTPS1 stability and mediating pyrimidine metabolism

  2025cites this paper
• Genome-scale knockout simulation and clustering analysis of drug-resistant breast cancer cells reveal drug sensitization targets

  2025cites this paper
• DLGAP5 enhances bladder cancer chemoresistance by regulating glycolysis through MYC stabilization

  2025cites this paper
• Emerging pathways yielding opportunities for future treatments in pancreatic ductal adenocarcinoma

  2025cites this paper
• NADH reductive stress drives metabolic reprogramming.

  2025cites this paper
• cNEK6 induces gemcitabine resistance by promoting glycolysis in pancreatic ductal adenocarcinoma via the SNRPA/PPA2c/mTORC1 axis

  2024influential citation
• The Role of Dicer Phosphorylation in Gemcitabine Resistance of Pancreatic Cancer

  2024cites this paper
• Unveiling the resistance to therapies in pancreatic ductal adenocarcinoma.

  2024cites this paper
• Clinical impact of carbonic anhydrase 9 expression on neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma.

  2024cites this paper
• KRT19 is regulated by miR-642a-5p and promotes pancreatic cancer progression through the Wnt/β-catenin pathway

  2024cites this paper
• Mucin1 as a potential molecule for cancer immunotherapy and targeted therapy

  2024cites this paper
• Genetics and biology of pancreatic ductal adenocarcinoma

  2024cites this paper
• Emerging mechanisms and promising approaches in pancreatic cancer metabolism

  2024cites this paper
• Addressing chemoresistance with a lipid gemcitabine nanotherapeutic strategy for effective treatment of pancreatic cancer

  2024cites this paper
• Insights into gemcitabine resistance in pancreatic cancer: association with metabolic reprogramming and TP53 pathogenicity in patient derived xenografts

  2024cites this paper
• GDNF-induced phosphorylation of MUC21 promotes pancreatic cancer perineural invasion and metastasis by activating RAC2 GTPase

  2024cites this paper
• TRIM65/NF2/YAP1 Signaling Coordinately Orchestrates Metabolic and Immune Advantages in Hepatocellular Carcinoma

  2024cites this paper
• The role of cytidine 5′‐triphosphate synthetase 1 in metabolic rewiring during epithelial‐to‐mesenchymal transition in non‐small‐cell lung cancer

  2024influential citation
• MicroRNAs as the pivotal regulators of Temozolomide resistance in glioblastoma

  2024cites this paper
• Maintenance Therapy for Pancreatic Cancer, a New Approach Based on the Synergy between the Novel Agent GP-2250 (Misetionamide) and Gemcitabine

  2024cites this paper
• DHODH inhibition enhances the efficacy of immune checkpoint blockade by increasing cancer cell antigen presentation

  2024cites this paper
• Advancements in the study of glucose metabolism in relation to tumor progression and treatment.

  2024cites this paper
• Current hotspots and trends in cancer metabolic reprogramming: a scientometric analysis

  2024cites this paper
• Prolactin receptor potentiates chemotherapy through miRNAs‐induced G6PD/TKT inhibition in pancreatic cancer

  2024cites this paper
• Targeting Neoantigens in Pancreatic Ductal Adenocarcinoma

  2024influential citation
• Redistribution of defective mitochondria-mediated dihydroorotate dehydrogenase imparts 5-fluorouracil resistance in colorectal cancer

  2024cites this paper
• Exploring the role of tRNA-derived small RNAs (tsRNAs) in disease: implications for HIF-1 pathway modulation

  2024cites this paper
• Single-cell transcriptomics reveal the prognostic roles of epithelial and T cells and DNA methylation-based prognostic models in pancreatic cancer

  2024cites this paper
• MUC1 promotes cervical squamous cell carcinoma through ERK phosphorylation-mediated regulation of ITGA2/ITGA3

  2024cites this paper
• Microbiome and metabolome analysis in smoking and non-smoking pancreatic ductal adenocarcinoma patients

  2024cites this paper
• Hypoxia, hypoxia-inducible factors and inflammatory bowel diseases

  2024cites this paper
• Regulation of Hypoxia Dependent Reprogramming of Cancer Metabolism: Role of HIF-1 and Its Potential Therapeutic Implications in Leukemia

  2024cites this paper
• Modulation of Epithelial–Mesenchymal Transition Is a Possible Underlying Mechanism for Inducing Chemoresistance in MIA PaCa-2 Cells against Gemcitabine and Paclitaxel

  2024cites this paper
• Exosome-Derived MicroRNA-221-3p Desensitizes Breast Cancer Cells to Adriamycin by Regulating PIK3r1-Mediated Glycose Metabolism

  2024cites this paper
• Biophysical interplay between extracellular matrix remodeling and hypoxia signaling in regulating cancer metastasis

  2024cites this paper
• The MUC1–HIF-1α signaling axis regulates pancreatic cancer pathogenesis through polyamine metabolism remodeling

  2024influential citation
• PRMT1 promotes pancreatic cancer development and resistance to chemotherapy

  2024cites this paper
• The Role of MUC1 in Renal Cell Carcinoma

  2024cites this paper
• GPRC5A promotes paclitaxel resistance and glucose content in NSCLC

  2024cites this paper
• LncRNAs as nodes for the cross-talk between autophagy and Wnt signaling in pancreatic cancer drug resistance

  2024cites this paper
• MUC1 and MUC16: critical for immune modulation in cancer therapeutics

  2024cites this paper
• GPX3-Mediated Oxidative Stress Affects Pyrimidine Metabolism Levels in Stomach Adenocarcinoma via the AMPK/mTOR Pathway

  2024cites this paper
• Metabolomic Investigations into Hypoxia-Mediated Metabolic Reprogramming of Pancreatic Cancer Cells.

  2024cites this paper
• Overcoming Microbiome-Acquired Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma

  2024cites this paper
• Advances in macrophage and T cell metabolic reprogramming and immunotherapy in the tumor microenvironment

  2024cites this paper
• Liensinine inhibits progression of intrahepatic cholangiocarcinoma by regulating TGF‐β1 /P‐smad3 signaling through HIF‐1a

  2024cites this paper
• Measurement of Metabolic Alteration in Immune Cells Under Hypoxia.

  2024cites this paper
• Sertraline/chloroquine combination therapy to target hypoxic and immunosuppressive serine/glycine synthesis-dependent glioblastomas

  2024cites this paper
• Integrative analysis of ultra-deep RNA-seq reveals alternative promoter usage as a mechanism of activating oncogenic programmes during prostate cancer progression

  2024cites this paper
• N6-methyladenosine modified TGFB2 triggers lipid metabolism reprogramming to confer pancreatic ductal adenocarcinoma gemcitabine resistance

  2024cites this paper
• SIRT7 knockdown promotes gemcitabine sensitivity of pancreatic cancer cell via upregulation of GLUT3 expression.

  2024cites this paper
• Targeting metabolic reprogramming to overcome drug resistance in advanced bladder cancer: insights from gemcitabine‐ and cisplatin‐resistant models

  2024cites this paper